Accutane, Sotret, Amnesteem and Claravis Linked to Ulcerative Colitis

A recent study published in The American Journal of Gastroenterology concluded that people were four (4) times more likely to develop Ulcerative colitis, a serious form of Infalmmatory Bowel Disease (IBD), when they took the following medications:

According to the study, as the dosage of Isotretinoin increased, so did the risk of developing Ulcerative Colitis and IBD.

What is Isotretinoin?

Isotretinoin, commonly known as generic Accutane and sold as Amnesteem, Claravis and Sotret, is a medication used to treat severe acne. Although this acne drug may work well to clear up acne, it also has a long list of dangerous side effects, including ulcerative colitis and Inflammatory Bowel Disease (IBD).

The American Journal of Gastroenterology Study

In this case-control study, scientists concluded that exposure to Accutane, Sotret, Claravis and Amnesteem was associated with an increased risk of Ulcerative Colitis and IBD. High doses of Sotret, Accutane, Claravis or Amnesteen acne medication and prolonged use were associated with the highest risk of Ulcerative Colitis.

The risk of developing Ulcerative Colitis was highest in those exposed to Isotretinoin for more than two (2) months. Meaning the risk of Ulcerative Colitis or Inflammatory Bowel Disease was increased for patients taking larger doses of Sotret, Accutane, Claravis or Amnesteen and those patients taking Accutane, Sotret, Claravis or Amnesteen for longer periods of time.

Contact an Accutane Lawsuit Attorney

If you or your loved one suffered from Ulcerative Colitis or IBD after taking Accutane or generic Accutane (Isotretinoin) as an acne treatment, please call us right away to speak with an experienced Accutane lawsuit attorney who specializes in defective pharmaceutical litigation and dangerous drug recall lawsuits. We can help you and your family to get the justice and compensation you need and deserve.

Feb. 1, 2011 | Tags: Accutane, Amnesteem, Claravis, Dangerous Drugs, Sotret

View All Legal News